Magnesium Citrate

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the relief of occasional constipation (irregularity). It generally produces a bowel movement within 1/2 to 6 hours of administration.

There are no teratogenic or nonteratogenic effects mentioned associated with this drug.

Dosage and Administration

The medication should be shaken well before use. It is recommended that patients drink a full glass (8 ounces) of liquid with each dose to ensure proper administration.

For adults and children aged 12 years and older, the dosage ranges from 6.5 to 10 fluid ounces, with a maximum limit of 10 fluid ounces within a 24-hour period.

For children aged 6 to under 12 years, the dosage is between 3 to 7 fluid ounces, not exceeding 7 fluid ounces in a 24-hour period.

For children aged 2 to under 6 years, the recommended dosage is 2 to 3 fluid ounces within a 24-hour timeframe, with a maximum of 3 fluid ounces allowed in that period.

For children under 2 years of age, it is advised to consult a physician for appropriate dosing recommendations.

The medication may be administered as a single daily dose or divided into multiple doses as deemed appropriate by the healthcare provider.

Contraindications

Use is contraindicated in patients experiencing rectal bleeding or failure to have a bowel movement after use, as these symptoms may indicate a serious underlying condition. In such cases, it is essential to discontinue use and consult a healthcare professional.

Warnings and Precautions

Patients with a history of kidney disease should exercise caution when using this medication, as it may exacerbate their condition. Additionally, individuals on a magnesium-restricted diet must be aware of the potential for increased magnesium levels, which could lead to serious complications.

Healthcare professionals should monitor patients for gastrointestinal symptoms such as abdominal pain, nausea, or vomiting. These symptoms may indicate an adverse reaction or intolerance to the medication. Furthermore, if a patient experiences a sudden change in bowel habits that persists for more than two weeks, it is imperative to evaluate the situation thoroughly, as this may signal an underlying issue requiring medical attention.

Patients who have been using a laxative for longer than one week should be advised to consult their healthcare provider before continuing treatment, as prolonged use may lead to dependency or other complications.

In the event of an overdose, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay to ensure appropriate management.

Patients must be instructed to discontinue use and contact their healthcare provider if they experience rectal bleeding or fail to have a bowel movement after using the medication. These symptoms could indicate a serious condition that necessitates prompt evaluation and intervention.

Side Effects

Patients should be aware of several important warnings associated with the use of this medication. Individuals with kidney disease or those on a magnesium-restricted diet should exercise caution. Additionally, patients experiencing abdominal pain, nausea, or vomiting should consider these symptoms as potential indicators of adverse reactions. A sudden change in bowel habits that persists for more than two weeks is also a significant concern, as is the use of a laxative for longer than one week.

Patients are advised to stop using the medication and consult a healthcare professional if they experience rectal bleeding or fail to have a bowel movement after use, as these symptoms may signify a serious underlying condition.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Magnesium Citrate (equate magnesium citrate oral solution - lemon). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older may receive a dosage of 6.5 to 10 fl oz, with a maximum limit of 10 fl oz in a 24-hour period. For children aged 6 to under 12 years, the recommended dosage is 3 to 7 fl oz, not exceeding 7 fl oz in 24 hours. In children aged 2 to under 6 years, the dosage is 2 to 3 fl oz, with a maximum of 3 fl oz in 24 hours.

For children under 2 years of age, it is advised to consult a doctor before administration. It is crucial to keep this product out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should consult a healthcare professional before using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. It is essential for women of childbearing potential to discuss their individual circumstances and any potential risks with their healthcare provider prior to use.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is no specific data available regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may require careful consideration regarding dosing adjustments and monitoring. In individuals with reduced kidney function, particularly those with kidney disease, it is essential to assess renal clearance to ensure appropriate therapeutic levels are maintained. Additionally, patients on a magnesium-restricted diet should be monitored closely, as renal impairment can affect magnesium levels and overall electrolyte balance. Regular evaluation of renal function is recommended to guide treatment decisions and minimize the risk of adverse effects.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient's condition is crucial. Recommended actions include:

1. Assessment: Conduct a thorough evaluation of the patient's vital signs and clinical status. Monitor for any signs of toxicity or adverse reactions.

2. Supportive Care: Initiate supportive measures as necessary, which may include airway management, oxygen supplementation, intravenous fluids, and monitoring in a controlled environment.

3. Decontamination: If the overdose is recent and the patient is alert, consider activated charcoal administration to limit further absorption of the substance. However, this should be avoided in cases of altered consciousness or risk of aspiration.

4. Specific Antidotes: If applicable, administer specific antidotes as indicated for the substance involved in the overdose. Familiarity with the appropriate antidotes and their administration protocols is essential.

5. Consultation: Engage with a poison control center or toxicology expert for guidance on management strategies tailored to the specific circumstances of the overdose.

6. Documentation: Ensure thorough documentation of the incident, including the substance involved, estimated dose, time of exposure, and all interventions performed.

In summary, while no specific overdosage information is provided, healthcare professionals should be prepared to act swiftly and effectively in managing potential overdose situations, utilizing established protocols and resources to ensure optimal patient outcomes.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of an overdose. It is important for patients to be aware of the signs that warrant discontinuation of the product; they should stop use and consult a doctor if they experience rectal bleeding or if they do not have a bowel movement after using the product, as these may indicate a serious condition.

Patients should also be encouraged to consult with their healthcare provider or pharmacist prior to using this product if they are currently taking any other medications. It is essential to inform patients that they should take this product at least 2 hours before or after taking other drugs, as laxatives may influence the effectiveness of other medications.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at temperatures ranging from 46° to 86°F (8° to 30°C) to maintain its efficacy and safety. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature range to prevent degradation.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Magnesium Citrate, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)